Bloomsbury Genetic Therapies launches with Seed financing of £5 million to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases
Bloomsbury Genetic Therapies Limited, a biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, based on clinically proven gene therapy technologies, has announced its launch with £5 million Seed financing led by UCL Technology Fund.
Four programmes have been licensed to BGT: Dopamine Transporter Deficiency Syndrome (DTDS) which received funding from MRC, GOSH charity, RT&BF; Niemann-Pick Disease Type C (NPC) which received funding from MRC, Asociacion Fuenlabrada, FundacionColombus, MRC DPFS; Infantile Neuroaxonal Dystrophy (INAD) which received funding from NBIA Association US, MRC DPFS; and Ornithine Transcarbamylase Deficiency (OTCD) which received funding from MRC, MRC DPFS, GOSH charity.
Bloomsbury’s innovative approach is designed to optimise therapeutic efficacy and safety, enable high manufacturability, accelerate development timelines and maximise regulatory success to create a pipeline of highly differentiated first- or best-in-class programs. The Company’s lead programs are liver and CNS targeted gene therapies.
Sara Garcia Gomez, Senior Business Manager at UCLB said, “We are really excited to see the launch of Bloomsbury GTx, and we look forward to seeing the acceleration of these UCL therapies into patients. It’s a great example of how UCLB works alongside academic excellence from UCL, to bring innovations to the real world for the benefit of society.”
Read the full announcement from Bloomsbury here.